| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(1 year, 6 months from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969369 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9161937 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9345701 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9084729 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9283216 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9056051 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9283221 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9168252 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9511066 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US8846090 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(5 months ago) | |
| US9555000 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(5 months ago) | |
| US9907793 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(5 months ago) | |
| US8846091 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(5 months ago) | |
Targiniq is owned by Purdue Pharma Lp.
Targiniq contains Naloxone Hydrochloride; Oxycodone Hydrochloride.
Targiniq has a total of 15 drug patents out of which 13 drug patents have expired.
Expired drug patents of Targiniq are:
- US8969369
- US9161937
- US9345701
- US9084729
- US9283216
- US9056051
- US9283221
- US9168252
- US9511066
- US8846090
- US9555000
- US9907793
- US8846091
Targiniq was authorised for market use on 23 July, 2014.
Targiniq is available in tablet, extended release;oral dosage forms.
Targiniq can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate by providing an abuse-deterrent oral controlled release combination drug product, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Targiniq are possible to be released after 30 March, 2025.
Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TARGINIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic